n-3 fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects

Am J Clin Nutr. 1996 Feb;63(2):261-6. doi: 10.1093/ajcn/63.2.261.

Abstract

Recent data suggest that treatment with n-3 fatty acids could enhance the susceptibility of plasma low-density-lipoprotein (LDL) to oxidation. Twelve hypertriacylglycerolemic, hemodialyzed patients were treated with 2.5 g n-3 fatty acids/d for 2 mo. Treatment was then withdrawn for 2 mo (washout phase). Plasma total cholesterol and LDL cholesterol increased significantly (9% and 28%) and plasma triacylglycerols decreased significantly after the n-3 phase compared with baseline and washout values. LDL susceptibility to oxidation was tested by oxidation of LDL particles with 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH). No significant changes were observed for the lag phase and the peroxidation rate. The vitamin E content of LDL also did not change significantly. The results thus suggest that a daily dosage of 2.5 g n-3 fatty acids does not enhance LDL susceptibility to oxidation, while retaining its hypotriacylglycerolemic effect.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidines / pharmacology
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood*
  • Fatty Acids, Omega-3 / pharmacology
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Humans
  • Hypertriglyceridemia / blood*
  • Hypertriglyceridemia / therapy
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / therapy
  • Lipid Peroxidation / drug effects*
  • Male
  • Middle Aged
  • Renal Dialysis*
  • Triglycerides / blood
  • Vitamin E / blood

Substances

  • Amidines
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Fatty Acids, Omega-3
  • Triglycerides
  • Vitamin E
  • 2,2'-azobis(2-amidinopropane)
  • Cholesterol